Current Infectious Disease Reports

, Volume 1, Issue 3, pp 230–237

Therapeutic approaches to streptococcal toxic shock syndrome

  • Gio J. Baracco
  • Alan L. Bisno
Article

Abstract

The streptococcal toxic shock syndrome (STSS) is a severe, life-threatening condition characterized by hypotension and multiorgan system dysfunction associated with infection by the group A Streptococcus (GAS) or rarely by streptococci of other Lancefield serogroups. It is associated with a soft tissue infection, such as necrotizing fasciitis, in about half of the cases; the remainder are secondary to a variety of other invasive and noninvasive GAS infections. Although the pathophysiology of STSS is not yet fully understood, there are compelling reasons to believe that the syndrome results at least in part from the action of the streptococcal pyrogenic exotoxins, which act as superantigens. Patients with STSS should be admitted to an intensive care unit for support of cardiovascular, respiratory, and renal function as required. In experimental models of overwhelming GAS infection, clindamycin has greater efficacy than penicillin, and therapy with this agent is recommended. Penicillin, to which GAS are uniformly susceptible, may be used in addition to clindamycin. Limited clinical experience, most of which is anecdotal, suggests marked improvement in some STSS patients after administration of intravenous immunoglobulin. Even in the absence of conclusive data, the potential benefits of intravenous immunoglobulin in this highly lethal disease make its use reasonable in life-threatening cases. Other experimental approaches are also discussed, such as the use of anti-tumor necrosis factor monoclonal antibodies and plasmapheresis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bisno AL, Stevens DL: Streptococcal infections in skin and soft tissues. N Engl J Med 1996, 334:240–245.PubMedCrossRefGoogle Scholar
  2. 2.
    Stevens DL: The toxic shock syndromes. Infect Dis Clin North Am 1996, 10:727–746.PubMedCrossRefGoogle Scholar
  3. 3.
    Stevens DL, Tanner MH, Winship J, et al.: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989, 321:1–7.PubMedGoogle Scholar
  4. 4.
    Meyer MA: Streptococcal toxic shock syndrome complicating pre-septal cellulitis. Am J Ophthalmol 1997, 123:841–843.PubMedGoogle Scholar
  5. 5.
    Arvand M, Schneider T, Jahn HU, Hahn H: Streptococcal toxic shock syndrome associated with marked gamma delta T cell expansion: case report. Clin Infect Dis 1996, 22:362–365.PubMedGoogle Scholar
  6. 6.
    Ralph ED, Bourne RB: Toxicshock syndrome in association with group-A streptococcal infection of a knee joint after a total knee arthroplasty: a case report. J Bone Joint Surg Am 1998, 80:96–98.PubMedGoogle Scholar
  7. 7.
    Devin B, McCarthy A, Mehran R, Auger C: Necrotizing fasciitis of the retroperitoneum: an unusual presentation of group A Streptococcus infection. Can J Surg 1998, 41:156–160.PubMedGoogle Scholar
  8. 8.
    Eriksson BKG, Andersson J, Holm SE, Norgren M: Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 1998, 27:1428–1436. Population-based surveillance of STSS cases occurring in Sweden. This report discusses risk factors for acquiring invasive GAS disease and developing STSS.PubMedGoogle Scholar
  9. 9.
    Zurawski CA, Bardsley M, Beall B, et al.: Invasive group A streptococcal disease in Metropolitan Atlanta: a population-based assessment. Clin Infect Dis 1998, 27:150–157.PubMedGoogle Scholar
  10. 10.
    Wagner JG, Schlievert PM, Assimacopoulos AP, et al.: Acute group G Streptococcus myositis associated with streptococcal toxic shock syndrome: case report and review. Clin Infect Dis 1996, 23:1159–1161.PubMedGoogle Scholar
  11. 11.
    Keiser P, Campbell W: Toxic strep syndrome associated with group C Streptococcus. Arch Intern Med 1992, 152:882–884.PubMedCrossRefGoogle Scholar
  12. 12.
    Efstratiou A: Pyogenic streptococci of Lancefield groups C and G as pathogens in man. Soc Appl Bacteriol Symp Series 1997, 26:72S-79S.Google Scholar
  13. 13.
    Schlievert PM, Gocke JE, Deringer JR: Group B streptococcal toxic shock-like syndrome: report of a case and purification of an associated pyrogenic toxin. Clin Infect Dis 1993, 17:26–31.PubMedGoogle Scholar
  14. 14.
    Gardam MA, Low DE, Saginur R, Miller MA: Group B streptococcal necrotizing fasciitis and streptococcal toxic shock-like syndrome in adults. Arch Intern Med 1998, 158:1704–1708.PubMedCrossRefGoogle Scholar
  15. 15.
    Hirose Y, Yagi K, Honda H, et al.: Toxic shock-like syndrome caused by non-group A beta-hemolytic streptococci. Arch Intern Med 1997, 157:1891–1894.PubMedCrossRefGoogle Scholar
  16. 16.
    Leelarasamee A, Nilakul C, Tien-Grim S, et al.: Streptococcus suis toxic-shock syndrome and meningitis (abstract). J Med Assoc Thai 1997, 80:63–68.PubMedGoogle Scholar
  17. 17.
    Davies HD, McGeer A, Schwartz B, et al., and the Ontario Group A Streptococcal Study Group: Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996, 335:547–554.PubMedCrossRefGoogle Scholar
  18. 18.
    Gonzales-Ruiz A, Ridgway GL, Cohen SL, et al.: Varicella gangrenosa with toxic shock-like syndrome due to group A Streptococcus infection in an adult: case report. Clin Infect Dis 1995, 20:1058–1060.Google Scholar
  19. 19.
    Nadal D, Lauener RP, Braegger CP, et al.: T cell activation and cytokine release in streptococcal toxic shock syndrome. J Pediatr 1993, 122:727–729.PubMedCrossRefGoogle Scholar
  20. 20.
    Yang YJ, Liu CC, Wang SM, et al.: Streptococcal toxic shock syndrome complicating varicella in children (abstract). J Formos Med Assoc 1997, 96:749–753.PubMedGoogle Scholar
  21. 21.
    Harada K, Suzuki T, Suzuki A, et al.: Toxic shock-like syndrome after acupuncturation [abstract]. Kansenshogaku Zasshi 1997, 71:1066–1070.PubMedGoogle Scholar
  22. 22.
    Stevens DL: Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 1995, 21:977–980.PubMedGoogle Scholar
  23. 23.
    Kaul R, McGeer A, Low D, et al.: Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiological analysis of seventy-seven cases. Am J Med 1997, 103:18–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Norrby-Teglund A, Newton D, Kotb M, et al.: Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun 1994, 62:5227–5233.PubMedGoogle Scholar
  25. 25.
    Stevens DL: Superantigens: their role in infectious diseases. Immun Invest 1997, 26:275–281.CrossRefGoogle Scholar
  26. 26.
    Johnson HM, Torres BA, Soos JM: Superantigens: structure and relevance to human disease. Proc Soc Exp Biol Med 1996, 212:99–109.PubMedGoogle Scholar
  27. 27.
    Michie C, Scott A, Cheesbrough J, et al.: Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin Exp Immunol 1994, 98:140–144.PubMedGoogle Scholar
  28. 28.
    Manders SM: Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998, 39:383–398.PubMedCrossRefGoogle Scholar
  29. 29.
    Norrby-Teglund A, Pauksens K, Norgren M, Holm SE: Correlation between serum TNFa and IL6 levels and severity of group A streptococcal infections. Scand J Infect Dis 1995, 27:125–130.PubMedGoogle Scholar
  30. 30.
    Muller-Alouf H, Gerlach D, Desreumaux P, et al.: Streptococcal pyrogenic exotoxin A (SPE A) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells. Microbial Pathogen 1997, 23:265–272. This article characterizes the superantigenic activity of SPE-A and its possible role in the pathogenesis of STSS.CrossRefGoogle Scholar
  31. 31.
    Muller-Alouf H, Alouf JE, Gerlach D, et al.: Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infect Immun 1994, 62:4915.PubMedGoogle Scholar
  32. 32.
    Lukomski S, Sreevatsan S, Amberg C, et al.: Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains. J Clin Invest 1997, 99:2574–2580.PubMedCrossRefGoogle Scholar
  33. 33.
    Kapur V, Majesky MW, Li L, et al.: Cleavage of interleukin 1b (IL-1b) precursor to produce active IL-1b by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci U S A 1993, 90:676–680.CrossRefGoogle Scholar
  34. 34.
    Stevens DL, Bryant AE, Hackett SP, et al.: Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996, 173:619–626.PubMedGoogle Scholar
  35. 35.
    Herwald H, Collin M, Muller-Esterl W, Bjorck L: Streptococcal cysteine proteinase releases kinins: a novel virulence mechanism. J Exp Med 1996, 184:665–673.PubMedCrossRefGoogle Scholar
  36. 36.
    Ichiyama S, Nakashima K, Shimokata K, et al.: Transmission of Streptococcus pyogenes causing toxic shock-like syndrome among family members and confirmation by DNA macrorestriction analysis. J Infect Dis 1997, 175:723–726.PubMedGoogle Scholar
  37. 37.
    Cockerill FR, MacDonald KL, Thompson RL, et al.: An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997, 277:38–43. This epidemiologic study demonstrated a high prevalence of asymptomatic carriage of an invasive GAS clone, thus raising the issue of the advisability of prophylaxis of contacts.PubMedCrossRefGoogle Scholar
  38. 38.
    Norrby-Teglund A, Pauksens K, Holm SE, Norgren M: Relations between low capacity of human sera to inhibit streptococcal mitogens and serious manifestations of disease. J Infect Dis 1994, 170:585–591.PubMedGoogle Scholar
  39. 39.
    Mahieu LM, Holm SE, Goosens HJ, Van Acker KJ: Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995, 127:987–989.PubMedCrossRefGoogle Scholar
  40. 40.
    Stevens DL: Editorial response: rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis 1998, 26:639–641.PubMedGoogle Scholar
  41. 41.
    The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993, 269:390–391.CrossRefGoogle Scholar
  42. 42.
    Centers for Disease Control and Prevention: Case definitions for infectious conditions under public health surveillance. Streptococcal toxic shock syndrome. MMWR 1997, 46:33–34.Google Scholar
  43. 43.
    Wood TF, Potter MA, Jonasson O: Streptococcal toxic shocklike syndrome: the importance of surgical intervention. Ann Surg 1993, 217:109–114.PubMedCrossRefGoogle Scholar
  44. 44.
    Berger-Jekic O, Vuckovic-Opavski N, Ranin L: Susceptibility of beta-hemolytic streptococci to penicillin. Adv Exp Med Biol 1997, 418:467–469.PubMedGoogle Scholar
  45. 45.
    Coonan KM, Kaplan EL: In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 1994, 13:630–635.PubMedGoogle Scholar
  46. 46.
    Holm SE: Invasive group A streptococcal infections (letter, comment). N Engl J Med 1996, 335:590–591.PubMedCrossRefGoogle Scholar
  47. 47.
    Stevens DL, Yan S, Bryant AE: Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo:an explanation of the inoculum effect. J Infect Dis 1993, 167:1401–1405.PubMedGoogle Scholar
  48. 48.
    Stevens DL, Gibbons AE, Bergstrom R, Winn V: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23–28.PubMedGoogle Scholar
  49. 49.
    Bisno AL, Stevens DL: Streptococcal infections. In Principles and Practice of Infectious Diseases, edn 5. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: WB Saunders; 1999, in press.Google Scholar
  50. 50.
    Stevens DL, Madaras-Kelly KJ, Richards DM: In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998, 42:1266–1268. Recent study evaluating the in vitro interaction between penicillin and clindamycin at clinical concentrations using time-kill studies for GAS.PubMedGoogle Scholar
  51. 51.
    Bisno AL, Gerber MA, Gwaltney JM, et al.: Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Clin Infect Dis 1997, 25:574–583.PubMedGoogle Scholar
  52. 52.
    Holdsworth RJ, Smith D, Parratt D, Gunn A: Treatment of invasive Streptococcus pyogenes infection with vancomycin. J R Coll Surg Edinb 1994, 39:185–188.PubMedGoogle Scholar
  53. 53.
    Barry W, Hudgins L, Donta ST, Pesanti EL: Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315–3316.PubMedCrossRefGoogle Scholar
  54. 54.
    Lamothe F, D’Amico P, Ghosn P, et al.: Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995, 21:1469–1470.PubMedGoogle Scholar
  55. 55.
    Chiu CH, Ou JT, Chang KSS, Lin TY: Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection 1997, 25:47–48.PubMedCrossRefGoogle Scholar
  56. 56.
    Perez CM, Kubak BM, Cryer HG, et al.: Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Am J Med 1997, 102:111–1113.PubMedCrossRefGoogle Scholar
  57. 57.
    Kaul R, McGeer A, Norrby-Teglund A, et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. Clin Infect Dis 1999, 28:800–807.PubMedGoogle Scholar
  58. 58.
    Mouthon L, Kaveri SV, Spalter SH, et al.: Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996, 104:3–9.PubMedGoogle Scholar
  59. 59.
    Norrby-Teglund A, Kaul R, Low DE, et al.: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996, 156:3057–3064.PubMedGoogle Scholar
  60. 60.
    Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U: Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996, 104:10–20.PubMedGoogle Scholar
  61. 61.
    Norrby-Teglund A, Kaul R, Low DE, et al.: Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996, 64:5395–5398.PubMedGoogle Scholar
  62. 62.
    Norrby-Teglund A, Basma H, Andersson J, et al.: Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998, 26:631–638.PubMedGoogle Scholar
  63. 63.
    Werdan K, Pilz G: Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 1996, 104:83–90.PubMedGoogle Scholar
  64. 64.
    Stegmayr B, Bjorck S, Holm S, et al.: Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand J Infect Dis 1992, 24:589–597.PubMedGoogle Scholar
  65. 65.
    Dale JB, Cleary PP, Fischetti VA, et al.: Group A and group B streptococcal vaccine development: a roundtable presentation. Adv Exp Med Biol 1997, 418:863–868.PubMedGoogle Scholar
  66. 66.
    DiPersio JR, File TM, Stevens DL, et al.: Spread of serious disease-producing M3 clones of group A Streptococcus among family members and health care workers. Clin Infect Dis 1996, 22:490–495.PubMedGoogle Scholar
  67. 67.
    Gamba MA, Martinelli M, Schaad HJ, et al.: Familial transmission of a serious disease-producing group A Streptococcus clone: case reports and review. Clin Infect Dis 1997, 24:1118–1121.PubMedGoogle Scholar
  68. 68.
    The Working Group on Prevention of Invasive Group A Streptococcal Infections: Prevention of invasive group A streptococcal disease among household contacts of case-patients. Is prophylaxis warranted? JAMA 1998, 279(15):1206–1210. This is an expert consensus statement regarding the use of prophylactic antimicrobials for household contacts of patients with invasive GAS disease. The available studies are well reviewed and analyzed, although lack of conclusive data precluded a clear recommendation.CrossRefGoogle Scholar
  69. 69.
    Morita J, Kahn E, Thompson T, et al.: Eradication of oropharyngeal group A Streptococcus (GAS) with azithromycin. In Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America. Denver, 1998:570 Sa.Google Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Gio J. Baracco
    • 1
  • Alan L. Bisno
    • 1
  1. 1.Department of Medicine, Division of Infectious DiseasesUniversity of Miami School of Medicine; Medical Service, Miami Veterans Affairs Medical Center (111)MiamiUSA

Personalised recommendations